title: Fibroblast growth factor 21-deficient mice demonstrate impaired adaptation to ketosis.
abstract: Fibroblast growth factor 21 (FGF21) is a key metabolic regulator. Expressed primarily in liver and adipose tissue, FGF21 is induced via peroxisome proliferator-activated receptor (PPAR) pathways during states requiring increased fatty acid oxidation including fasting and consumption of a ketogenic diet. To test the hypothesis that FGF21 is a physiological regulator that plays a role in lipid oxidation, we generated mice with targeted disruption of the Fgf21 locus (FGF21 knockout). Mice lacking FGF21 had mild weight gain and slightly impaired glucose homeostasis, indicating a role in long-term energy homeostasis. Furthermore, FGF21KO mice tolerated a 24-h fast, indicating that FGF21 is not essential in the early stages of starvation. In contrast to wild-type animals in which feeding KD leads to dramatic weight loss, FGF21KO mice fed KD gained weight, developed hepatosteatosis, and showed marked impairments in ketogenesis and glucose control. This confirms the physiological importance of FGF21 in the adaptation to KD feeding. At a molecular level, these effects were accompanied by lower levels of expression of PGC1alpha and PGC1beta in FGF21KO mice, strongly implicating these key transcriptional regulators in the action of FGF21. Furthermore, within the liver, the maturation of the lipogenic transcription factor sterol regulatory element-binding protein-1c was increased in FGF21KO mice, implicating posttranscriptional events in the maladaptation of FGF21KO mice to KD. These data reinforce the role of FGF21 is a critical regulator of long-term energy balance and metabolism. Mice lacking FGF21 cannot respond appropriately to a ketogenic diet, resulting in an impaired ability to mobilize and utilize lipids.
authors.affiliation: Associate Professor of Medicine, Division of Endocrinology, Diabetes, and Metabolism, Beth Israel Deaconess Medical Center, Center for Life Sciences, 7th Floor, 330 Brookline Avenue, Boston, Massachusetts 02215, USA.
authors.forename: Michael K
authors.initials: MK
authors.lastname: Badman
authors.forename: Anja
authors.initials: A
authors.lastname: Koester
authors.forename: Jeffrey S
authors.initials: JS
authors.lastname: Flier
authors.forename: Alexei
authors.initials: A
authors.lastname: Kharitonenkov
authors.forename: Eleftheria
authors.initials: E
authors.lastname: Maratos-Flier
mesh_terms: D000818:Animals; D055423:Diet, Ketogenic / Q000009:adverse effects; D004195:Disease Models, Animal; D004734:Energy Metabolism; D005234:Fatty Liver / Q000378:metabolism; D005260:Female; D005346:Fibroblast Growth Factors / Q000172:deficiency* / Q000235:genetics*; D020868:Gene Silencing; D005947:Glucose / Q000378:metabolism; D006801:Humans; D007662:Ketosis / Q000235:genetics / Q000378:metabolism*; D050356:Lipid Metabolism; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout
chemical_list: C414620:fibroblast growth factor 21; D005346:Fibroblast Growth Factors; D005947:Glucose